Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$11.77
$0.53(4.50%)
At close: 4:00 PM EDT
$11.77
$0.53(4.50%)
Day’s Range― - ―
52-Week Range$6.62 - $15.35
Previous Close$12.35
Volume585.80K
Average Volume (3M)1.06M
Market Cap
$1.20B
Enterprise Value$1.24K
Total Cash (Recent Filing)$143.17M
Total Debt (Recent Filing)$112.32M
Price to Earnings (P/E)16.7
Beta1.63
Next Earnings
Nov 18, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.76
Shares Outstanding92,609,510
10 Day Avg. Volume681,602
30 Day Avg. Volume1,056,260
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.20Price Target Upside97.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$33.38M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA sustained ~94% gross margin reflects a high-value revenue mix and durable pricing or IP advantage in gene therapy. Such strong unit economics mean incremental revenue can flow to EBITDA quickly as fixed R&D and SG&A scale, supporting long-term cash generation if revenue grows.
Operating Cash Flow Turned PositiveConversion to positive operating cash flow (~$8M TTM) signals improving core cash generation from operations rather than financing. If sustained, this reduces dependence on capital markets, funds ongoing development, and underpins a more durable path to self‑funding commercialization investments.
Material Financing & Program ConsolidationThe royalty financing package and equity raise materially extend runway into 2H 2028 while redeeming prior debt, reducing near-term default risk. Reacquiring program rights centralizes commercialization upside and strategic control, strengthening ability to fund pivotal trials and capture value long term.
Bears Say
Negative Stockholders' EquityNegative equity indicates cumulative losses have eroded capital, limiting balance sheet flexibility. This raises the likelihood of future dilutive financings or structured transactions, constrains unsecured borrowing capacity, and increases vulnerability to adverse shocks or covenant triggers over months.
Large Recurring Net LossesSizable TTM net losses (~$121M) versus modest revenue show the business has yet to scale cost structure to profitability. Persistent negative margins require material revenue growth or significant cost discipline to reach break-even, pressuring long-term sustainability without continued external funding.
Negative And Volatile Free Cash FlowSlightly negative FCF and sharp year-over-year deterioration reflect ongoing heavy investment and working-capital volatility. Even with positive operating cash flow, inconsistent FCF suggests continued financing need to support R&D and commercialization, raising dilution and execution risk over the medium term.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings’s price range in the past 12 months?
Meiragtx Holdings lowest stock price was $6.62 and its highest was $15.35 in the past 12 months.
What is Meiragtx Holdings’s market cap?
Meiragtx Holdings’s market cap is $1.20B.
When is Meiragtx Holdings’s upcoming earnings report date?
Meiragtx Holdings’s upcoming earnings report date is Nov 18, 2026 which is in 96 days.
How were Meiragtx Holdings’s earnings last quarter?
Meiragtx Holdings released its earnings results on Aug 13, 2026. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of -$0.458 by $2.168.
Is Meiragtx Holdings overvalued?
According to Wall Street analysts Meiragtx Holdings’s price is currently Undervalued.
Does Meiragtx Holdings pay dividends?
Meiragtx Holdings does not currently pay dividends.
What is Meiragtx Holdings’s EPS estimate?
Meiragtx Holdings’s EPS estimate is -0.5.
How many shares outstanding does Meiragtx Holdings have?
Meiragtx Holdings has 92,609,510 shares outstanding.
What happened to Meiragtx Holdings’s price movement after its last earnings report?
Meiragtx Holdings reported an EPS of $1.71 in its last earnings report, beating expectations of -$0.458. Following the earnings report the stock price went down -2.238%.
Which hedge fund is a major shareholder of Meiragtx Holdings?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.20 (97.11% Upside)
$23.20 (97.11% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 144.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 10.6%
Last 30 Days ▼ 10.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Meiragtx Holdings
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$23.20
▲(97.11% Upside)
Technical Analysis
Ownership Overview
15.56% Insiders
1.86% Mutual Funds
22.76% Other Institutional Investors
54.04% Public Companies and
Individual Investors